Epigenetic regulation in myelodysplastic syndromes: implications for therapy. - Wikidata - wikimedia - TriplyDB

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

http://www.wikidata.org/entity/Q37850456

about

The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism Current therapy of myelodysplastic syndromes Epigenetics and the overhealing wound: the role of DNA methylation in fibrosis.Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes.Epigenetics, development, and cancer: zebrafish make their mark..HDAC inhibitors in HIV.Epigenetic-based therapies in cancer: progress to date.Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Understanding chronic neutropenia: life is short.Panobinostat for the treatment of acute myelogenous leukemia.

P2860

Q33846421-284D1D87-DC55-42F2-A9DA-74F15275AEC1 Q34013796-3C8C00F9-5AA2-4C97-9EE3-6E805AC43D71 Q36113039-B85F1227-FE98-4201-B310-6C3C3E7AA571 Q36862388-495BCC12-AFA6-49E6-B6D1-22E964F16723 Q37889228-7AB1B29D-E59E-4331-91C4-E4C31AF52686 Q37956178-CA2CFFB1-E792-4F74-B5BA-70DB21E5478B Q37964702-97A70EE9-A039-4583-810F-7F43F0758393 Q38074249-486D4353-36F4-4AC2-A3AF-779EEE198AF1 Q38540859-952AC732-CA9C-4F2E-8938-81266C95CBA2 Q38604646-53091BB3-6E1D-41C6-83BD-A809D412CD89 Q38835113-6DFF5BBB-5875-4E37-A08B-D6D292621D2A

P2860

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

http://www.wikidata.org/entity/Q37850456

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

@en

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

@nl

type

label

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

@en

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

@nl

prefLabel

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

@en

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

@nl

P1433

Q37850456-6928E62C-8A5B-4E85-9BE2-064AE7857528

P1476

Q37850456-51C48CA3-9912-4EAC-89CC-902CA0B06F9C

P2093

Q37850456-0B86D928-E83D-43BA-870F-9E0DA003BCA7

Q37850456-3BC1433B-C1AA-4597-8B33-5DAE32A11980

Q37850456-528E70DD-DB0E-4F29-9460-AFD9D3EDDFD2

Q37850456-7551BE66-398C-4586-89C9-295F96EEF8E2

Q37850456-953A2A21-7A2A-452B-965A-171C126A4A9D

Q37850456-97EE8629-CEE2-492F-8402-78272A586362

Q37850456-A0B5755A-BC78-4330-8EC0-622723612407

Q37850456-B67E2867-D7DD-4C10-989B-C4691C241AC2

Q37850456-B6C90ABC-CBEE-47CE-8A76-EF7E93952F18

Q37850456-BCC63EC0-8827-4F00-9307-A0FA76B0331D

P2860

Q37850456-04642057-18D3-432D-BFD1-A0DED0A98A54

Q37850456-074051F2-63F1-4FA5-9F32-C15635C36211

Q37850456-09B71717-54C8-4CA7-98AD-0B0A43EC07C8

Q37850456-0AA9F316-1CEC-4A7C-B294-2138057CEFC4

Q37850456-0AC1F879-9AB1-4464-96FF-57A176F0414C

Q37850456-0ADCF4F6-1C79-4D30-A16A-F5EA36EC062A

Q37850456-0B9834F9-CF32-4E76-8F9C-7B27E97FD567

Q37850456-0BA8AEB5-5855-44D9-B8FB-12356C3F1503

Q37850456-0E1EACDE-6086-4F25-BB07-2B3455379BE2

Q37850456-1079F88D-39CC-4F70-9E8D-49BE829747FF

P304

Q37850456-F50244E2-B2A2-4B62-BD25-E68C421D3065

P31

Q37850456-1B34BF98-4422-49F8-84E9-249863E73923

P356

Q37850456-EAB2986C-AA1C-4C0C-B5A6-84207908C1A8

P407

Q37850456-CF8C1A07-57BA-4902-AE50-7B0828A5F665

P433

Q37850456-CF755581-2EE2-4FE8-A667-E8A97D498DF9

P478

Q37850456-A83F2284-0BB2-445C-B3FB-78659E644F62

P50

Q37850456-6394DDE8-F6EA-4D9D-8AF3-C1B466BC32B8

P577

Q37850456-54D0FFA0-A5A6-4B3D-8E79-27C03B6EDD9C

P698

Q37850456-CFB2C7E1-C5AD-49FA-8EAA-1441FD4779BE

P356

13543784.2011.559164

P1433

Expert Opinion on Investigational Drugs

P1476

Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

@en

P2093

Antonio Madeo

http://www.w3.org/2001/XMLSchema#string

Carla Mazzone

http://www.w3.org/2001/XMLSchema#string

Carlo Gentile

http://www.w3.org/2001/XMLSchema#string

Ernesto Vigna

http://www.w3.org/2001/XMLSchema#string

Eugenio Lucia

http://www.w3.org/2001/XMLSchema#string

Filippo Fimognari

http://www.w3.org/2001/XMLSchema#string

Fortunato Morabito

http://www.w3.org/2001/XMLSchema#string

Laura De Stefano

http://www.w3.org/2001/XMLSchema#string

Lucio Morabito

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Bisconte

http://www.w3.org/2001/XMLSchema#string

P2860

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

Silencing of microRNAs in vivo with 'antagomirs'

P304

465-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2011.559164

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Anna Grazia Recchia

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21381982

http://www.w3.org/2001/XMLSchema#string